AMENDMENTS TO THE CLAIMS

Please amend claims 24-26 as indicated below. Please add new claims 27-36. Please cancel claims 11, 12, 18, 19, 22, and 23. Deletions appear in ~~strikethrough font~~, and additions are underlined.

Complete listing of claims

1. (Previously presented) A compound of the formula I,



I

in which

R^1 is (C_1-C_8)-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C_1-C_4)-alkoxy, (C_1-C_4)-alkyl-$S(O)_m$-, R^5R^6N and aryl; (C_3-C_9)-cycloalkyl, which can be substituted by one or more identical or different substituents chosen from (C_1-C_4)-alkyl, hydroxyl and amino; or a radical of a 5-membered to 7-membered saturated heterocyclic ring with one or two identical or different hetero ring members chosen from O, NR^7 and $S(O)_m$ and that can be substituted by one or more identical or different substituents chosen from (C_1-C_4)-alkyl and aryl-(C_1-C_4)-alkyl-; and

R^2 is hydrogen, (C_1-C_8)-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C_1-C_4)-alkoxy, (C_1-C_4)-

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

alkyl-$S(O)_m$-, R^5R^6N and aryl; (C_3-C_9)-cycloalkyl, which can be substituted by one or more identical or different substituents chosen from (C_1-C_4)-alkyl, hydroxyl and amino; or the radical of a 5-membered to 7-membered saturated heterocyclic ring with one or two identical or different hetero ring members chosen from O, NR^7 and $S(O)_m$ and that can be substituted by one or more identical or different substituents chosen from (C_1-C_4)-alkyl and aryl-(C_1-C_4)-alkyl-; or

R^1R^2N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated heterocyclic ring optionally with, in addition to the nitrogen atom carrying the radicals R^1 and R^2, a further hetero ring member chosen from O, NR^7 and $S(O)_m$ and that can be substituted by one or more identical or different substituents chosen from (C_1-C_4)-alkyl, hydroxyl, (C_1-C_4)-alkoxy, R^8R^9N, hydroxycarbonyl, (C_1-C_4)-alkoxycarbonyl and R^8R^9N-CO-;

R^3 is phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, (C_1-C_4)-alkyl, phenyl, CF_3, NO_2, OH, -O-(C_1-C_4)-alkyl, -O-(C_2-C_4)-alkyl-O-(C_1-C_4)-alkyl, (C_1-C_2)-alkylenedioxy, NH_2, -NH-(C_1-C_4)-alkyl, N((C_1-C_4)-alkyl)$_2$, -NH-CHO, -NH-CO-(C_1-C_4)-alkyl, -CN, -CO-NH_2, -CO-NH-(C_1-C_4)-alkyl, -CO-N((C_1-C_4)-alkyl)$_2$, -CO-OH, -CO-O-(C_1-C_4)-alkyl, -CHO and –CO-(C_1-C_4)-alkyl;

R^4 is (C_2-C_5)-alkyl, trifluoromethyl or phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, (C_1-C_4)-alkyl, phenyl, CF_3, NO_2, OH, -O-(C_1-C_4)-alkyl, -O-(C_2-C_4)-alkyl-O-(C_1-C_4)-alkyl, (C_1-C_2)-alkylenedioxy, NH_2, -NH-(C_1-C_4)-alkyl, N((C_1-C_4)-alkyl$_2$, -NH-CHO, -NH-CO-(C_1-C_4)-alkyl, -CN, -CO-NH_2, -CO-NH-(C_1-C_4)-alkyl, -CO-N((C_1-C_4)-alkyl$_2$, -CO-OH, -CO-O-(C_1-C_4)- alkyl, -CHO and –CO-(C_1-C_4)-alkyl;

R^5 and R^6 are identical or different radicals chosen from hydrogen and (C_1-C_4)-alkyl; or the group R^5R^6N is a radical, bonded via a ring nitrogen atom, of

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

a 5-membered to 7-membered saturated or unsaturated heterocyclic ring optionally with, in addition to the nitrogen atom carrying the radicals R^5 and R^6, a further hetero ring member chosen from an oxygen atom, a group $S(O)_m$ and a nitrogen atom and that can carry on ring carbon atoms one or more identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxyl and amino and that can carry on a ring nitrogen atom a radical R^7;

R^7 is hydrogen, $(C_1$-$C_4)$-alkyl, aryl-$(C_1$-$C_4)$-alkyl-, hydroxy-$(C_1$-$C_4)$-alkyl, hydroxycarbonyl-$(C_1$-$C_4)$-alkyl-, $((C_1$-$C_4)$-alkoxycarbonyl)-$(C_1$-$C_4)$-alkyl, R^8R^9N-CO-$(C_1$-$C_4)$-alkyl-, R^{10}-SO_2- or aryl; where R^7, if this group is present on a piperazino radical representing R^1R^2N, cannot be carbocyclic aryl or carbocyclic aryl-$(C^1$-$C^4)$-alkyl;

R^8 and R^9 are identical or different radicals chosen from hydrogen and $(C_1$-$C_4)$-alkyl;

R^{10} is $(C_1$-$C_4)$-alkyl, aryl or R^8R^9N;

aryl is phenyl, naphthyl or heteroaryl, all of which can be substituted by one or more identical or different substituents chosen from halogen, $(C_1$-$C_4)$-alkyl, phenyl, CF_3, NO2, OH, -O-$(C_1$-$C_4)$-alkyl, O-$(C_2$-$C_4)$-alkyl-O-$(C_1$-$C_4)$-alkyl, $(C_1$-$C_2)$-alkylenedioxy, NH_2, -NH-$(C_1$-$C_4)$-alkyl, -N$((C_1$-$C_4)$-$alkyl_2$, -NH-CHO, -NH-CO-$(C_1$-$C_4)$-alkyl, -CN, CO-NH_2, -CO-NH-$(C_1$-$C_4)$-alkyl, -CO-N$((C_1$-$C_4)$-$alkyl_2$, -CO-OH, -CO-O-$(C_1$-$C_4)$-alkyl, -CHO and –CO-$(C_1$-$C_4)$-alkyl;

heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or of a bicyclic 8-membered to 10-membered aromatic heterocycle, each of which with one or two identical or different ring heteroatoms chosen from N, O and S;

m is 0, 1 or 2;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

or a stereoisomeric form of a compound of formula I,

or a mixture of stereoisomeric forms of compounds of formula I in all ratios,

or a physiologically tolerable salt of a compound of formula I,

or a physiologically tolerable salt of a stereoisomeric form of a compound of formula I;

compounds of the formula I being excluded in which, simultaneously, R^4 is ethyl, tert-butyl, or trifluoromethyl; R^3 is phenyl, which can be substituted by one or two identical or different substituents chosen from halogen, OH, -O-R^{11} and CF_3, R^1R^2N is R^{11} -NH-, $(R^{11})_2N$- or $R^{12}R^{13}N$-$(CH_2)_p$-NH-; p is 2 or 3; R^{11} is saturated unsubstituted $(C_1$-$C_4)$-alkyl; and R^{12} and R^{13} are identical or different radicals chosen from hydrogen and R^{11} or the group $R^{12}R^{13}N$ is a radical, bonded via a ring nitrogen atom, of a 5-membered or 6-membered saturated heterocyclic ring optionally with, in addition to the nitrogen atom carrying the radicals R^{12} and R^{13}, a further hetero ring member chosen from an oxygen atom, a sulfur atom and a nitrogen atom and that can be substituted by an aryl substituted by one or two identical or different substituents chosen from halogen, OH, -O-R^{11}, and CF_3.

2. (Previously presented) A compound of claim 1, in which

R^1 is $(C_1$-$C_8)$-alkyl, which can be substituted by one or more identical or different substituents, chosen from, hydroxyl, $(C_1$-$C_4)$-alkoxy, $(C_1$-$C_4)$-alkyl-$S(O)_m$-, R^5R^6N and aryl; or is $(C_3$-$C_9)$-cycloalkyl, which can be substituted by one or more identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxyl and amino; and

R^2 is hydrogen, $(C_1$-$C_8)$-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, $(C_1$-$C_4)$-alkoxy, $(C_1$-$C_4)$-alkyl-$S(O)_m$-, R^5R^6N and aryl; or is $(C_3$-$C_9)$-cycloalkyl, which can be

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

substituted by one or more identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxyl and amino; or

R^1R^2N is a radical, bonded via a ring nitrogen atom of a 5-membered, 6-membered or 7-membered saturated heterocyclic ring optionally with, in addition to the nitrogen atom carrying the radicals R^1 and R^2, a further hetero ring member chosen from an oxygen atom, a group $S(O)_m$ and a nitrogen atom carrying a radical R^7 and that can be substituted by one or more identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxyl, $(C_1$-$C_4)$-alkoxy, R^8R^9N, hydroxycarbonyl, $(C_1$-$C_4)$-alkoxycarbonyl and R^8R^9N-CO.

3. (Previously presented) A compound of claim 1, in which R^1 is $(C_1$-$C_4)$-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, $(C_1$-$C_4)$-alkoxy, $(C_1$-$C_4)$-alkyl-$S(O)_m$-, R^5R^6N and aryl, or $(C_3$-$C_9)$-cycloalkyl, which can be substituted by one or more identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxyl and amino, and R^2 is hydrogen; or R^1 and R^2 are identical or different $(C_1$-$C_4)$-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, $(C_1$-$C_4)$-alkoxy, $(C_1$-$C_4)$-alkyl-$S(O)_m$-, R^5R^6N and aryl.

4. (Previously presented) A compound of claim 1, in which R^1 is $(C_3$-$C_9)$-cycloalkyl, which can be substituted by one or more identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxyl and amino, and R^2 is hydrogen.

5. (Previously presented) A compound of claim 1, in which R^1R^2N- is an unsubstituted or substituted radical chosen from piperidino, morpholino and thiomorpholino (and its S-oxide and S,S-dioxide) and piperazino.

6. (Previously presented) A compound of claim 1, in which R^3 is substituted phenyl.

7. (Previously presented) A compound of claim 1, in which R^4 is $(C_3$-$C_4)$-alkyl.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

8. (Previously presented) A process for the preparation of at least one compound of claim 1, which comprises activating a 4-hydroxypyrimidine of the formula IV and then reacting it with an amine of a formula VI to produce a compound of formula I,



and optionally converting a compound of formula I into a pharmaceutically acceptable salt.

Claims 9-12 (Cancelled)

13. (Previously presented) A compound of claim 5, in which R^3 is substituted phenyl.

14. (Previously presented) A compound of claim 5, in which R^4 is $(C_3\text{-}C_4)$-alkyl.

15. (Previously presented) A process for the preparation of at least one compound of claim 5, which comprises activating a 4-hydroxypyrimidine of the formula IV and then reacting it with an amine of a formula VI;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



and optionally converting the resulting product into a pharmaceutically acceptable salt.

Claims 16-19 (Cancelled)

20. (Previously presented) A pharmaceutical composition, comprising one or more compounds of claim 1 and a pharmaceutically acceptable carrier.

21. (Previously presented) A pharmaceutical composition, comprising one or more compounds of claim 5 and a pharmaceutically acceptable carrier.

Claims 22-23 (Cancelled)

24. (Currently amended) A method of treating ~~according to claim 12, wherein the cardiovascular disorder is~~ angina pectoris, comprising administering to a patient in need thereof an effective amount of at least one compound of claim 1.

25. (Currently amended) A method of treating ~~according to claim 19, wherein the cardiovascular disorder is~~ angina pectoris, comprising administering to a patient in need thereof an effective amount of at least one compound of claim 5.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

26. (Currently amended) A method of treating ~~according to claim 23, wherein the cardiovascular disorder is~~ angina pectoris, comprising administering to a patient in need thereof an effective amount of at least one compound of formula I,



I

in which

R^1 is (C_1-C_8)-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C_1-C_4)-alkoxy, (C_1-C_4)-alkyl-$S(O)_m$-, R^5R^6N and aryl; (C_3-C_9)-cycloalkyl, which can be substituted by one or more identical or different substituents chosen from (C_1-C_4)-alkyl, hydroxyl and amino; or a radical of a 5-membered to 7-membered saturated heterocyclic ring with one or two identical or different hetero ring members chosen from O, NR^7 and $S(O)_m$ and that can be substituted by one or more identical or different substituents chosen from (C_1-C_4)-alkyl and aryl-(C_1-C_4)-alkyl-; and

R^2 is hydrogen, (C_1-C_8)-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, (C_1-C_4)-alkoxy, (C_1-C_4)-alkyl-$S(O)_m$-, R^5R^6N and aryl; (C_3-C_9)-cycloalkyl, which can be substituted by one or more identical or different substituents chosen from (C_1-C_4)-alkyl, hydroxyl and amino; or the radical of a 5-membered to 7-membered saturated heterocyclic ring with one or two identical or different hetero ring members chosen from O, NR^7 and $S(O)_m$ and that can be substituted by

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

one or more identical or different substituents chosen from $(C_1$-$C_4)$-alkyl and aryl-$(C_1$-$C_4)$-alkyl-; or

R^1R^2N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated heterocyclic ring optionally with, in addition to the nitrogen atom carrying the radicals R^1 and R^2, a further hetero ring member chosen from O, NR^7 and $S(O)_m$ and that can be substituted by one or more identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxyl, $(C_1$-$C_4)$-alkoxy, R^8R^9N, hydroxycarbonyl, $(C_1$-$C_4)$-alkoxycarbonyl and R^8R^9N-CO-;

R^3 is phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, $(C_1$-$C_4)$-alkyl, phenyl, CF_3, NO_2, OH, -O-$(C_1$-$C_4)$-alkyl, -O-$(C_2$-$C_4)$-alkyl-O-$(C_1$-$C_4)$-alkyl, $(C_1$-$C_2)$-alkylenedioxy, NH_2, -NH-$(C_1$-$C_4)$-alkyl, N($(C_1$-$C_4)$-alkyl)$_2$, -NH-CHO, -NH-CO-$(C_1$-$C_4)$-alkyl, -CN, -CO-NH_2, -CO-NH-$(C_1$-$C_4)$-alkyl, -CO-N($(C_1$-$C_4)$-alkyl)$_2$, -CO-OH, -CO-O-$(C_1$-$C_4)$-alkyl, -CHO and –CO-$(C_1$-$C_4)$-alkyl;

R^4 is $(C_2$-$C_5)$-alkyl, trifluoromethyl or phenyl, which can be substituted by one or more identical or different substituents chosen from halogen, $(C_1$-$C_4)$-alkyl, phenyl, CF_3, NO_2, OH, -O-$(C_1$-$C_4)$-alkyl, -O-$(C_2$-$C_4)$-alkyl-O-$(C_1$-$C_4)$-alkyl, $(C_1$-$C_2)$-alkylenedioxy, NH_2, -NH-$(C_1$-$C_4)$-alkyl, N($(C_1$-$C_4)$-alkyl$_2$, -NH-CHO, -NH-CO-$(C_1$-$C_4)$-alkyl, -CN, -CO-NH_2, -CO-NH-$(C_1$-$C_4)$-alkyl, -CO-N($(C_1$-$C_4)$-alkyl$_2$, -CO-OH, -CO-O-$(C_1$-$C_4)$- alkyl, -CHO and –CO-$(C_1$-$C_4)$-alkyl;

R^5 and R^6 are identical or different radicals chosen from hydrogen and $(C_1$-$C_4)$-alkyl; or the group R^5R^6N is a radical, bonded via a ring nitrogen atom, of a 5-membered to 7-membered saturated or unsaturated heterocyclic ring optionally with, in addition to the nitrogen atom carrying the radicals R^5 and R^6, a further hetero ring member chosen from an oxygen atom, a group $S(O)_m$ and a nitrogen atom and that can carry on ring carbon atoms one or more identical or different substituents chosen from $(C_1$-$C_4)$-alkyl,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

hydroxyl and amino and that can carry on a ring nitrogen atom a radical R^7;

R^7 is hydrogen, $(C_1$-$C_4)$-alkyl, aryl-$(C_1$-$C_4)$-alkyl-, hydroxy-$(C_1$-$C_4)$-alkyl, hydroxycarbonyl-$(C_1$-$C_4)$-alkyl-, $((C_1$-$C_4)$-alkoxycarbonyl)-$(C_1$-$C_4)$-alkyl, R^8R^9N-CO-$(C_1$-$C_4)$-alkyl-, R^{10}-SO_2- or aryl; where R^7, if this group is present on a piperazino radical representing R^1R^2N, cannot be carbocyclic aryl or carbocyclic aryl-$(C^1$-$C^4)$-alkyl;

R^8 and R^9 are identical or different radicals chosen from hydrogen and $(C_1$-$C_4)$-alkyl;

R^{10} is $(C_1$-$C_4)$-alkyl, aryl or R^8R^9N;

aryl is phenyl, naphthyl or heteroaryl, all of which can be substituted by one or more identical or different substituents chosen from halogen, $(C_1$-$C_4)$-alkyl, phenyl, CF_3, NO2, OH, -O-$(C_1$-$C_4)$-alkyl, O-$(C_2$-$C_4)$-alkyl-O-$(C_1$-$C_4)$-alkyl, $(C_1$-$C_2)$-alkylenedioxy, NH_2, -NH-$(C_1$-$C_4)$-alkyl, -N$((C_1$-$C_4)$-$alkyl_2$, -NH-CHO, -NH-CO-$(C_1$-$C_4)$-alkyl, -CN, CO-NH_2, -CO-NH-$(C_1$-$C_4)$-alkyl, -CO-N$((C_1$-$C_4)$-$alkyl_2$, -CO-OH, -CO-O-$(C_1$-$C_4)$-alkyl, -CHO and –CO-$(C_1$-$C_4)$-alkyl;

heteroaryl is the radical of a monocyclic 5-membered or 6-membered aromatic heterocycle or of a bicyclic 8-membered to 10-membered aromatic heterocycle, each of which with one or two identical or different ring heteroatoms chosen from N, O and S;

m is 0, 1 or 2;

or a stereoisomeric form of a compound of formula I,

or a mixture of stereoisomeric forms of compounds of formula I in all ratios,

or a physiologically tolerable salt of a compound of formula I,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

or a physiologically tolerable salt of a stereoisomeric form of a compound of formula I.

27. (New) A compound of claim 1, in which R^1 is $(C_3$-$C_7)$-cycloalkyl, which can be substituted by one or two identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxyl and amino, and R^2 is hydrogen.

28. (New) A compound of claim 1, in which R^1 is $(C_3$-$C_9)$-cycloalkyl, which is substituted by hydroxyl and R^2 is hydrogen.

29. (New) A compound of claim 1, in which R^1 is cyclopentyl or cyclohexyl, wherein said cyclopentyl or cyclohexyl can be substituted by one or more identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxyl and amino, and R^2 is hydrogen.

30. (New) A compound of claim 1, in which R^1 is cyclopentyl or cyclohexyl, wherein said cyclopentyl or cyclohexyl is substituted by one or two identical or different substituents chosen from $(C_1$-$C_4)$-alkyl, hydroxyl and amino, and R^2 is hydrogen.

31. (New) A compound of claim 1, in which R^1 is cyclopentyl or cyclohexyl, wherein said cyclopentyl or cyclohexyl is substituted by hydroxyl, and R^2 is hydrogen.

32. (New) A compound of claim 1, in which R^1 is cyclohexyl, which is substituted by hydroxyl and R^2 is hydrogen.

33. (New) A compound of claim 1, in which R^1 is 4-hydroxycyclohexyl and R^2 is hydrogen.

34. (New) A compound of claim 1, in which R^1 is $(C_1$-$C_8)$-alkyl, which can be substituted by one or more identical or different substituents chosen from hydroxyl, $(C_1$-$C_4)$-alkoxy, $(C_1$-$C_4)$-alkyl-$S(O)_m$-, R^5R^6N- and aryl, and R^2 is hydrogen.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

35. (New) A compound of claim 1, in which

R^1R^2N is cyclopentylamino, R^3 is 4-methylphenyl, and R^4 is isopropyl; or

R^1R^2N is (trans-4-hydroxycyclohexyl)amino, R^3 is 4-methylphenyl, and R^4 is isopropyl; or

R^1R^2N is cyclopropylamino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (trans-4-hydroxycyclohexyl)amino, R^3 is 3,5-dichlorophenyl, and R^4 is isopropyl; or

R^1R^2N is cyclopentylamino, R^3 is 4-cyanophenyl, and R^4 is isopropyl; or

R^1R^2N is (4-hydroxycyclohexyl)amino, R^3 is 4-cyanophenyl, and R^4 is isopropyl; or

R^1R^2N is cyclopentylamino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (trans-4-hydroxycyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (trans-4-aminocyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (cis/trans-4-hydroxycyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (4-methylcyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (2-isopropyl-5-methylcyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (trans-2-hydroxycyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R^1R^2N is cyclopentylamino, R^3 is 4-chlorophenyl, and R^4 is tert-butyl; or

R^1R^2N is (trans-4-hydroxycyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is tert-butyl; or

R^1R^2N is cyclopentylamino, R^3 is 4-chlorophenyl, and R^4 is CF^3, or

R^1R^2N is (trans-4-hydroxycyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is phenyl; or

R^1R^2N is cyclobutylamino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is cyclononylamino, R^3 is 4-chlorophenyl, and R^4 is isopropyl.

36. (New) A compound of claim 1, wherein in the formula I

R^1R^2N is (trans-4-hydroxycyclohexyl)amino, R^3 is 4-methylphenyl, and R^4 is isopropyl; or

R^1R^2N is (trans-4-hydroxycyclohexyl)amino, R^3 is 3,5-dichlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (4-hydroxycyclohexyl)amino, R^3 is 4-cyanophenyl, and R^4 is isopropyl: or

R^1R^2N is (trans-4-hydroxycyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (cis/trans-4-hydroxycyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (trans-2-hydroxycyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is isopropyl; or

R^1R^2N is (trans-4-hydroxycyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is tert-butyl; or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R^1R^2N is (trans-4-hydroxycyclohexyl)amino, R^3 is 4-chlorophenyl, and R^4 is phenyl.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com